Inhibition of platelet-dependent prothrombinase activity and thrombin generation by glycoprotein IIb/IIIa receptor-directed antagonists: Potential contributing mechanism of benefit in acute coronary syndromes

Journal of Thrombosis and Thrombolysis

Volumn 10, Issue 1, 2000, Pages 69-76

  Li, Y ^a   Spencer, F A ^a   Ball, S ^a   Becker, R C ^a  

^a UNIVERSITY OF MASSACHUSETTS   (United States)

Author keywords

Anticoagulants; Glycoprotein IIb IIIa receptor antagonists; Low molecular weight heparin; Platelet aggregation; Unfractionated heparin

Indexed keywords

ABCIXIMAB; BLOOD CLOTTING FACTOR 10A; EPTIFIBATIDE; GLYCOPROTEIN IIB; GLYCOPROTEIN IIIA; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; THROMBIN; TIROFIBAN;

ARTICLE; CORONARY ARTERY DISEASE; ENZYME ACTIVITY; ERYTHROCYTE; ERYTHROCYTE AGGREGATION; HUMAN; HUMAN CELL; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0033802667     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018754906289     Document Type: Article

References (27)

1. Unstable angina with fatal outcome: Dynamic coronary thrombosis leading to infarction and/or sudden death. Autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion
2. Intramyocardial platelet aggregation in patients with unstable angina suffering sudden ischemic cardiac death
3. Characterization of the relative thrombogenicity of atherosclerotic plaque components: Implications for consequences of plaque rupture
4. The clinical use of flow cytometry for assessing platelet activation in acute coronary syndrome
5. Dynamic nature of thrombin generation, fibrin formation, and platelet activation in unstable angina and non-Q-wave myocardial infarction
6. Platelet activation determined by flow cytometry persists despite antithrombotic therapy in patients with unstable angina and non-Q-wave myocardial infarction
7. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thromboasthenic-like state in normal patients and binds to glycoprotein IIb and/or IIIa
8. Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (The EPIC Trial)
9. The role of GTP-binding proteins in platelet activation
10. Surface-dependent reactions of the vitamin K-dependent enzyme complexes
11. 3) inhibitors
12. Thrombin binding to platelets and their activation in plasma
13. In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonist c7E3 Fab on the activated clotting time
14. Administration of abciximab during percutaneous coronary intervention reduces both ex vivo platelet thrombus formation and fibrin deposition. Implications for a potential anticoagulant effect of abciximab
15. Randomized trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: Results at six months
16. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina
17. Inhibition of the platelet glycoprotein IIb/IIIa receptor and tirofiban in unstable angina and non-Q wave myocardial infarction
18. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes
19. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody
20. Expression of markers of platelet activation and the interpatient variation in response to abciximab
21. Platelet activation in patients after an acute coronary syndrome: Results from the TIMI-12 trial
22. Platelet glycoprotein IIb/IIIa receptor blockade and low dose heparin during percutaneous coronary revascularization
23. Enoxaparin, a low molecular weight heparin, inhibits platelet-dependent prothrombinase assembly and activity by factor Xa neuralization
24. Effects of platelet glycoprotein IIb/IIIa inhibition with abciximab on thrombin generation and activity during percutaneous coronary intervention
25. A comparison of low molecular weight heparin with unfractionated heparin for unstable coronary artery disease
26. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the TIMI 11B Trial
27. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-Essence Meta-Analysis